Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Tango Therapeutics ( (TNGX) ) is now available.
On January 8, 2026, Tango Therapeutics announced a planned leadership transition in which founding chief executive Barbara Weber, M.D., retired from the CEO role and became Executive Chair for 2026, moving to non-executive chair in 2027, while remaining involved in strategic priorities and clinical execution; the company emphasized that her departure from the CEO position was not due to any disagreement over operations or policies. Effective the same day, board member and oncology veteran Malte Peters, M.D., was appointed President and Chief Executive Officer with a compensation and equity package designed to align him with long-term shareholder value, as Tango renewed its 2026 clinical guidance for key milestones, including registrational and combination studies of vopimetostat and early-stage data from TNG456, underscoring management’s focus on advancing its precision oncology pipeline into pivotal development and potential commercialization.
The most recent analyst rating on (TNGX) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.
Spark’s Take on TNGX Stock
According to Spark, TipRanks’ AI Analyst, TNGX is a Neutral.
The score is held back primarily by weak financial performance—ongoing losses and negative cash flows—despite strong revenue growth and low leverage. Technicals are constructive with a clear uptrend but look overbought, while valuation remains pressured due to lack of profitability; corporate events are moderately supportive due to added funding and governance improvements.
To see Spark’s full report on TNGX stock, click here.
More about Tango Therapeutics
Tango Therapeutics, Inc. (NASDAQ: TNGX) is a Boston-based clinical-stage biotechnology company focused on discovering and developing next-generation precision cancer medicines, including its lead PRMT5 inhibitor vopimetostat and other targeted oncology candidates aimed at genetically defined patient populations.
Average Trading Volume: 3,327,516
Technical Sentiment Signal: Buy
Current Market Cap: $1.3B
Find detailed analytics on TNGX stock on TipRanks’ Stock Analysis page.